The 2026 World Alzheimer Report is now available: A New Era of Dementia Clinical Trials! Dementia clinical trials are bringing new opportunities alongside important questions about how we make research more inclusive, accessible and effective to enable emerging and future innovation for dementia treatments. The 2026 World Alzheimer Report explores key issues including recruitment participation and retention, the importance of global representation, diversification and their impact on inclusive dementia research, and the need to increase awareness and understanding of clinical trials among medical practitioners. The report also explores what clinical trials are and how they work, while sharing personal perspectives and experiences from people involved in clinical research. By bringing together evidence and lived experiences, the report shines a light on recommendations to ensure the next generation of dementia clinical trials are fit to deliver global innovation for future treatments. Download the 2026 World Alzheimer Report today: bit.ly/4iF82gQ #WorldAlzReport #WorldAlzheimerReport #DementiaClinicalTrials #WorldAlzMonth

Register for our upcoming 2026 World Alzheimer Report launch webinar, where leading experts and report contributors will explore the new era of dementia clinical trials, the human stories behind them, what participation means for a person living with dementia and what these trials could mean for the future of diagnosis, treatment and care. Register here: bit.ly/4xWzDyx Registrants will receive a download link to the report during the webinar and via email afterward, along with exclusive first access to the event recording, giving registrants the opportunity to revisit the top insights from the discussion. About the report 📌 The 2026 World Alzheimer Report explores key issues including recruitment participation and retention, the importance of global representation, diversification and their impact on inclusive dementia research, and the need to increase awareness and understanding of clinical trials among medical practitioners. The report also explores what clinical trials are and how they work, while sharing personal perspectives and experiences from people involved in clinical research. By bringing together evidence and lived experiences, the report shines a light on recommendations to ensure the next generation of dementia clinical trials are fit to deliver global innovation for future treatments. Register today and join us as we launch the 2026 edition of the World Alzheimer Report. We look forward to welcoming you.

There is just one week remaining before the launch of the 2026 World Alzheimer Report, focusing this year on dementia clinical trials. You don't need to be a neuroscientist to decipher the report! The report illuminates how clinical trials work and how they are experienced by those participating, as well as highlights the challenges to the dementia treatment pipeline. Ahead of the launch, ADI is sharing an early preview into the report for our global network. Chapter 2, 'Understanding clinical trials: How new dementia treatments are developed,' provides an accessible introduction to clinical trials and foundational explanations of how new dementia treatments are developed through the rigorous clinical trial process. Clinical trials are the foundation of modern medicine, providing the evidence needed to determine whether new treatments are safe, effective, and suitable for widespread use. Every medicine currently prescribed for Alzheimer’s disease and other forms of dementia has reached people affected by the condition only after progressing through stages of scientific testing. This chapter follows the journey of a potential medicine from laboratory discovery, through testing in cells and animals, into carefully designed studies involving people, and ultimately to regulatory approval and use in everyday clinical practice. It explains the different phases of clinical trials, why most experimental treatments fail, and why the drug development process, although slow and expensive, is critical for protecting patients and generating reliable evidence. The chapter will unpack terms such as “Phase 3,” “placebo-controlled,” and “double-blind,” explaining what they mean in the context of developing a potential dementia treatment, as well as examining what these development pipelines mean in a global context, including the complex organisational and research structures through which potential treatments are developed, tested, and brought towards clinical use. To learn more about how new dementia treatments are developed, register for our World Alzheimer Report 2026 launch webinar: A new era in dementia clinical trials, taking place on 21 September 2026 at 14:00 BST. Register today! bit.ly/4xWzDyx #WorldAlzheimerReport #DementiaClinicalTrials #WorldAlzMonth #DementiaDiagnosisMatters #AlzheimerDiagnosisMatters